Treatment of Insomnia in Post-Acute Withdrawal Syndrome (PAWS)

The American Academy of Sleep Medicine suggests that insomnia is extremely common in post-acute withdrawal syndrome, affecting a significant portion of individuals with lifetime alcohol dependence, with some patients experiencing insomnia peaks as late as several months after abstinence 1, 2

First-Line Treatment: CBT-I

The American College of Physicians recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for insomnia in PAWS, providing superior long-term outcomes and addressing the underlying mechanisms maintaining insomnia without risk of dependence 1, 3
CBT-I can be delivered through individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books, showing effectiveness, with treatment typically requiring 4-8 sessions over 6 weeks, and improvements being gradual but sustained for up to 2 years 1, 3

The American Academy of Sleep Medicine recommends stimulus control therapy, sleep restriction therapy, cognitive therapy, and relaxation training as core components of CBT-I 4, 3

The American Academy of Sleep Medicine suggests that benzodiazepines and benzodiazepine receptor agonists (BzRAs) should be avoided as first-line agents due to the substantial risk of dependence and withdrawal symptoms in PAWS patients 2, 5, 6, 7
The American College of Physicians recommends ramelteon, melatonin, and trazodone as preferred initial pharmacological options for PAWS patients, with ramelteon being a non-DEA-scheduled medication particularly appropriate for patients with substance use history 2, 4, 5, 6

The American Academy of Sleep Medicine advises that second-generation antipsychotics, such as quetiapine, should not be prescribed for insomnia alone due to significant metabolic side effects, including metabolic syndrome 5, 7, 6
The American College of Physicians recommends avoiding over-the-counter antihistamines, such as diphenhydramine and hydroxyzine, due to lack of efficacy data, daytime sedation, and risk of delirium 8, 2

The American Academy of Sleep Medicine suggests initiating CBT-I immediately as the cornerstone of treatment, and if CBT-I alone is insufficient after 2-4 weeks, adding ramelteon or melatonin while continuing CBT-I 1, 3, 2, 4
The American College of Physicians recommends using the lowest effective dose for the shortest duration possible, with regular reassessment every few weeks, and attempting medication tapering when conditions allow, facilitated by concurrent CBT-I 8, 1, 4

The American Academy of Sleep Medicine advises never prescribing benzodiazepines or BzRAs as first-line treatment in PAWS patients, and avoiding combining multiple sedative medications, which significantly increases risks of cognitive impairment, falls, and complex sleep behaviors 2, 5, 6, 7
The American College of Physicians recommends not relying on sleep hygiene education alone, as it lacks efficacy as a single intervention, and must be combined with other CBT-I components 3

The American Academy of Sleep Medicine suggests reassessing patients every 1-2 weeks initially to evaluate efficacy on sleep latency, sleep maintenance, daytime functioning, and monitor for adverse effects, and educating patients about treatment goals, realistic expectations, safety concerns, and the importance of behavioral treatments 2, 4, 3
The American College of Physicians recommends screening for underlying sleep disorders, such as sleep apnea and restless legs syndrome, if insomnia persists beyond 7-10 days of treatment, and monitoring for relapse risk 2